53BP1 loss elicits cGAS-STING-dependent antitumor immunity in ovarian and pancreatic cancer

· 2024-08-06

53BP1 nucleates the anti-end resection machinery at DNA double-strand breaks, thereby countering BRCA1 activity. Loss of 53BP1 leads to DNA end processing and homologous recombination in BRCA1-deficient cells. Consequently, BRCA1-mutant tumors, typically sensitive to PARP inhibitors (PARPi), become resistant in the absence of 53BP1. Here, we demonstrate that the 'leaky' DNA end resection in the absence of 53BP1 results in increased micronuclei and cytoplasmic double-stranded DNA, leading to activation of the cGAS-STING pathway and pro-inflammatory signaling. This enhances CD8
Funding

NCI NIH HHS

R01 CA208244

U.S. Department of Defense (United States Department of Defense)

W81XWH-15-0564/OC140632

NCI NIH HHS

R01 CA264900

U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)

CA208244

NCI NIH HHS

R01 CA248306

NCI NIH HHS

P30 CA006516

U.S. Department of Health & Human Services | NIH | National Cancer Institute

CA208244

U.S. Department of Defense

W81XWH-15-0564/OC140632

Gray Foundation Team Science Award